| Literature DB >> 32651579 |
Aakriti Gupta1,2,3, Mahesh V Madhavan1,2, Kartik Sehgal4,5,6, Nandini Nair7, Shiwani Mahajan3,8, Tejasav S Sehrawat9, Behnood Bikdeli1,2,3, Neha Ahluwalia10, John C Ausiello7, Elaine Y Wan1, Daniel E Freedberg11, Ajay J Kirtane2, Sahil A Parikh1,2, Mathew S Maurer1, Anna S Nordvig12, Domenico Accili7, Joan M Bathon13, Sumit Mohan14,15, Kenneth A Bauer4,6, Martin B Leon1,2, Harlan M Krumholz3,8,16, Nir Uriel1, Mandeep R Mehra17, Mitchell S V Elkind12,15, Gregg W Stone2,18, Allan Schwartz1, David D Ho19, John P Bilezikian7, Donald W Landry20.
Abstract
Although COVID-19 is most well known for causing substantial respiratory pathology, it can also result in several extrapulmonary manifestations. These conditions include thrombotic complications, myocardial dysfunction and arrhythmia, acute coronary syndromes, acute kidney injury, gastrointestinal symptoms, hepatocellular injury, hyperglycemia and ketosis, neurologic illnesses, ocular symptoms, and dermatologic complications. Given that ACE2, the entry receptor for the causative coronavirus SARS-CoV-2, is expressed in multiple extrapulmonary tissues, direct viral tissue damage is a plausible mechanism of injury. In addition, endothelial damage and thromboinflammation, dysregulation of immune responses, and maladaptation of ACE2-related pathways might all contribute to these extrapulmonary manifestations of COVID-19. Here we review the extrapulmonary organ-specific pathophysiology, presentations and management considerations for patients with COVID-19 to aid clinicians and scientists in recognizing and monitoring the spectrum of manifestations, and in developing research priorities and therapeutic strategies for all organ systems involved.Entities:
Mesh：
Year: 2020 PMID： 32651579 DOI： 10.1038/s41591-020-0968-3
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440